within Pharmacolibrary.Drugs.C_CardiovascularSystem.C10B_LipidModifyingAgentsCombinations.C10BA02_SimvastatinAndEzetimibe;

model SimvastatinAndEzetimibe
  extends Pharmacolibrary.Drugs.ATC.C.C10BA02;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>C10BA02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Simvastatin and ezetimibe is a fixed-dose combination medication used to lower cholesterol levels and is indicated for the treatment of primary hypercholesterolemia and mixed dyslipidemia. Simvastatin is an HMG-CoA reductase inhibitor (statin) reducing endogenous cholesterol synthesis, while ezetimibe inhibits intestinal absorption of cholesterol. The combination is approved and used today for patients who require further LDL-C reduction after statin monotherapy.</p><h4>Pharmacokinetics</h4><p>Typical pharmacokinetic parameters are reported for healthy adults after single oral administration. Simvastatin and ezetimibe are considered to have independent PK profiles. No population PK models for this fixed combination are published, so parameters are based on known average values from monotherapies and product characteristics.</p><h4>References</h4><ol><li><p>Kosoglou, T, et al., &amp; Alton, KB (2005). Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. <i>Clinical pharmacokinetics</i> 44(5) 467–494. DOI:<a href=\"https://doi.org/10.2165/00003088-200544050-00002\">10.2165/00003088-200544050-00002</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/15871634/\">https://pubmed.ncbi.nlm.nih.gov/15871634</a></p></li><li><p>Chu, NN, et al., &amp; Li, XN (2012). Pharmacokinetics and safety of ezetimibe/simvastatin combination tablet: an open-label, single-dose study in healthy Chinese subjects. <i>Clinical drug investigation</i> 32(12) 791–798. DOI:<a href=\"https://doi.org/10.1007/s40261-012-0013-5\">10.1007/s40261-012-0013-5</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/23109219/\">https://pubmed.ncbi.nlm.nih.gov/23109219</a></p></li><li><p>Bahetibieke, S, et al., &amp; Qi, R (2022). Co-Amorphous Formation of Simvastatin-Ezetimibe: Enhanced Physical Stability, Bioavailability and Cholesterol-Lowering Effects in LDLr-/-Mice. <i>Pharmaceutics</i> 14(6) –. DOI:<a href=\"https://doi.org/10.3390/pharmaceutics14061258\">10.3390/pharmaceutics14061258</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35745830/\">https://pubmed.ncbi.nlm.nih.gov/35745830</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end SimvastatinAndEzetimibe;
